[CAS NO. 174722-31-7]  Rituximab (anti-CD20)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [174722-31-7]

Catalog
HY-P9913A
Brand
MCE
CAS
174722-31-7

DESCRIPTION [174722-31-7]

Overview

MDL-
Molecular Weight144544.44
Molecular FormulaUnspecified
SMILES[Rituximab (anti-CD20)]

For research use only. We do not sell to patients.


Summary

Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer [1] .


In Vitro

Rituximab (anti-CD20) inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab [1] . All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab (anti-CD20) induces high CDC killing of follicular lymphoma cells [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT04978584 M.D. Anderson Cancer Center
Diffuse Large B-Cell Lymphoma
March 3, 2022 Phase 2
NCT03834688 PrECOG, LLC.|Genentech, Inc.
Mantle Cell Lymphoma
January 13, 2020 Phase 2
NCT03332888 Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
Heart Failure With Reduced Ejection Fraction
January 1, 2021 Phase 2

Appearance

Liquid


Storage

Please store the product under the recommended conditions in the Certificate of Analysis.



Synonyms

Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 γ1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer
Immunoglobulin G 1 (human-mouse monoclonal IDEC-C2B8 γ1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer
IDEC 102
Rituximab
IDEC-C 2B8
Rituxan
MabThera
Retuxin
5: PN: WO2008003319 PAGE: 45 claimed protein
Reditux
Kikuzubam
GP 2013
1: PN: WO2016077505 PAGE: 164 claimed sequence
RG 105